HPV Vaccine: Who Should Get It, When, and What to Record

HPV vaccination is one of the most impactful preventive interventions available — it can eliminate most cervical cancer and prevent several other cancers. India recently launched an indigenous HPV vaccine (Cervavac) making the vaccine much more affordable. Understanding who benefits, when to get it, and what to document is the specific work of using this vaccine well.

Who should be vaccinated

• Girls 9-14 years — primary target group, best immune response, two-dose schedule.
• Girls and women 15-26 — three-dose catch-up if not previously.
• Women 27-45 — case-by-case with doctor discussion (approved in India up to 45).
• Boys 9-14 — increasingly recommended; protects against genital warts, oral/anal cancers, and reduces community transmission.
• Anyone with weakened immune system — even outside standard age ranges.

Available vaccines in India

• Vaccine: Cervavac (SII, indigenous) · Types covered: 4 types (6,11,16,18) · Dose: 2 or 3 doses · Approximate cost (private): ₹2,000-3,000 total
• Vaccine: Gardasil 9 · Types covered: 9 types (6,11,16,18,31,33,45,52,58) · Dose: 2 or 3 doses · Approximate cost (private): ₹10,000-15,000 total
• Vaccine: Cervarix · Types covered: 2 types (16,18) · Dose: 2 or 3 doses · Approximate cost (private): ₹8,000-12,000 total

The dosing schedule

• Age 9-14: 2 doses, 6-12 months apart.
• Age 15+: 3 doses at 0, 1-2, and 6 months.
• Immunocompromised: always 3 doses.
• Once vaccinated, no boosters needed (as far as current evidence shows).

What HPV vaccine prevents

• Cervical cancer (nearly 100% caused by HPV) — 70-90% reduction possible with vaccine.
• Anal cancer (mostly HPV-related).
• Oropharyngeal cancer (rising incidence, largely HPV-driven).
• Penile cancer.
• Vulvar and vaginal cancers.
• Genital warts.

What HPV vaccine does NOT do

• Does not treat existing HPV infection.
• Does not replace cervical cancer screening (Pap/HPV testing continues).
• Does not protect against other STIs.
• Does not affect fertility (persistent myth without evidence).

Common concerns and their reality

• Safety: extensively studied; side effects usually injection site pain, mild fever, fatigue.
• Timing: earlier is better because immune response is stronger and it works best before HPV exposure.
• Sexual activity link: giving to 12-year-olds doesn't encourage earlier sex; evidence shows no effect on behaviour.
• Cost: with Cervavac now available, cost is much less of a barrier.
• Effectiveness: real-world data shows dramatic cancer reduction where vaccination is widespread (Australia, Scotland).

What to record

• Vaccine given (which brand).
• Date of each dose.
• Any reaction observed.
• Confirmation of series completion.
• For girls: ensure this is in place before cervical screening becomes routine.

The specific catch-up decisions

• Adult women who never received HPV vaccine — up to 45 in India, worth discussing.
• Women with abnormal Pap history — vaccine still beneficial after treatment.
• Post-hysterectomy women — vaccine still protects against other HPV cancers.
• Boys and men who never received — increasingly recommended.

What still matters despite vaccination

• Cervical cancer screening from age 25-30 continues.
• Practicing safer sex still matters — HPV vaccine doesn't cover other STIs.
• Regular gynaecological care continues.
• Non-vaccinated HPV types still exist.

HPV vaccination should be in every Indian teenage girl's health record by age 14. Widespread vaccination could eliminate most cervical cancer within a generation — a specific public health outcome few other interventions can match.

References

• MoHFW — HPV vaccine introduction India
• WHO — HPV vaccination)
• SII — Cervavac information